Genetic Polymorphism of Human Cytochrome P450 Involved in Drug Metabolism

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 3, 2002, Pages 167-189

  Nagata, Kiyoshi ^a   Yamazoe, Yasushi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

cytochrome P450; drug metabolizing enzymes; genotype; individual difference; polymorphism

Indexed keywords

EID: 85013917085     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.167     Document Type: Review

References (153)

1. Gonzalez, F. J.: The molecular biology of cytochrome P450s. Pharmacol. Rev., 40: 243-288 (1989).
2. Guengerich, F. P.: Human Cytochrome P450 enzymes: Cytochrome P450: Structure, Mechanism, and Biochemistry (Second Edition), (P. R. Ortiz de Montellano ed.) Plenum press, New York, 1995, pp. 473-535.
3. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C. and Nebert, D. W.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6: 1-42 (1996).
4. Xu, G., Salen, G., Shefer, S., Ness, G. C., Chen, T. S., Zhao, Z. and Tint, G. S.: Reproducing abnormal cholesterol biosynthesis as seen in the Smith-Lemli-Opitz syndrome by inhibiting the conversion of 7-dehydrocholesterol to cholesterol in rats. J. Clin. Invest, 95: 76-81 (1995).
5. White, P. C.: Steroid 11 ε-hydroxylase deficiency and related disorders. Endocrinol Metab Clin. North Am, 30: 61-79 (2001).
6. Lee, H.: CYP21 mutations and congenital adrenal hyperplasia. Clin. Genet., 59: 293-301 (2001).
7. Nebert, D. W., Nelson, D. R., Adesnik, M., Coon, M. J., Estabrook, R. W., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Kemper, B., Levin, W., Phillips, I. R., Sato, R. and Waterman, M. R.: The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA, 8: 1-13 (1989).
8. Lawton, M. P., Cashman, J. R., Cresteil, T., Dolphin, C. T., Elfarra, A. A., Hines, R. N., Hodgson, E., Kimura, T., Ozols, J., Phillips, I. R., Philpot, R. M., Poulsen, L. L., Rettie, A. E., Shephard, E. A., Williiams, D. E. and Ziegler, D. M.: A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch. Biochem. Biophys., 308: 254-257 (1994).
9. Vatsis, K. P., Weber, W. W., Bell, D. A., Dupret, J. M., Evans, D. A., Grant, D. M., Hein, D. W., Lin, H. J., Meyer, U. A., Relling, M. V., Sim, E., Suzuki, T. and Yamazoe, Y.: Nomenclature for N-acetyltran-sferases. Pharmacogenetics, 5: 1-17 (1995).
10. Beetham, J. K., Grant, D., Arand, M., Garbarino, J., Kiyosue, T., Pinot, F., Oesch, F., Belknap, W. R., Shinozaki, K. and Hammock, B. D.: Gene evolution of epoxide hydrolases and recommended nomenclature. DNA Cell Biol., 14: 61-71 (1995).
11. Meyer, U. A.: Genetic polymorphisms of drug metabolism. pundam Clin. Pharmacol., 4: 595-615 (1990).
12. Nebert, D. W., Adesnik, M., Coon, M. J., Estabrook, R. W., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Kemper, B., Levin, W., Phillips, I. R., Sato, R. and Waterman, M. R.: The P450 gene superfamily: recommended nomenclature. DNA, 6: 1-11 (1987).
13. Rendic, S. and Di Carlo, F. J.: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 29: 413-580 (1997).
14. Jaiswal, A. K., Gonzalez, F. J. and Nebert, D. W.: Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. Nucleic Acids. Res., 13: 4503-4520 (1985).
15. Smart, J. and Daly, A. K.: Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics, 10: 11-24 (2000).
16. Hayashi, S. I., Watanabe, J., Nakachi, K. and Kawajiri, K.: PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids. Res., 19: 4797 (1991).
17. Persson, I., Johansson, I., and Ingelman-Sundberg, M.: In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem. Biophys. Res. Commun., 231: 227-230 (1997).
18. Crofts, F., Cosma, G. N., Currie, D., Taioli, E., Toniolo, P. and Garte, S. J.: A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis, 14: 1729-1731 (1993).
19. Cascorbi, I., Brockmoller, J. and Roots, I.: A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res., 56: 4965-4969 (1996).
20. Chevalier, D., Allorge, D., Lo-Guidice, J. M., Cauffiez, C., Lhermitte, M., Lafitte, J. J. and Broly, F.: Detection of known and two novel (M331I and R464S) missense mutations in the human CYP1A1 gene in a French Caucasian population. Hum. Mutat., 17: 355 (2001).
21. Quattrochi, L. C. and Tukey, R. H.: The human cytochrome Cyp1A2 gene contains regulatory elements responsive to 3-methylcholanthrene. Mol. Pharmacol., 36: 66-71 (1989).
22. Ikeya, K., Jaiswal, A. K., Owens, R. A., Jones, J. E., Nebert, D. W. and Kimura, S.: Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol. Endocrinol., 3: 1399-1408 (1989).
23. Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F. and Kamataki, T.: Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev., 3: 413-421 (1994).
24. Nakajima, M., Yokoi, T., Mizutani, M., Kinoshita, M., Funayama, M. and Kamataki, T.: Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem., 125: 803-808 (1999).
25. Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J. and Kamataki, T.: Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn. J. Cancer Res., 90: 899-902 (1999).
26. Sachse, C., Brockmoller, J., Bauer, S., and Roots, I.: Functional significance of a C-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol., 47: 445-449 (1999).
27. Chevalier, D., Cauffiez, C., Allorge, D., Lo-Guidice, J. M., Lhermitte, M., Lafitte, J. J. and Broly, F.: Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population. Hum. Mutat., 17: 355356 (2001).
28. Huang, J. D., Guo, W. C., Lai, M. D., Guo, Y. L. and Lambert, G. H.: Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab. Dispos., 27: 98-101 (1999).
29. Welfare, M., Aitkin, M., Bassendine, M. and Daly, A.: Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics, 9: 367-375 (1999).
30. Tang, Y. M., Wo, Y. Y., Stewart, J., Hawkins, A. L., Griffin, C. A., Sutter, T. R. and Greenlee, W. F.: Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J. Biol. Chem., 271: 28324-28330 (1996).
31. Stoilov, I., Akarsu, A. N. and Sarfarazi, M.: Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet., 6: 641-647 (1997).
32. Aklillu, E., Oscarson, M., Hidestrand, M., Leidvik, B., Otter, C. and Ingelman-Sundberg, M.: Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol. Pharmacol., 61: 586-594 (2002).
33. Stoilov, I., Akarsu, A. N., Alozie, I., Child, A., Barsoum-Homsy, M., Turacli, M. E., Or, M., Lewis, R. A., Özdemir, N., Brice, G., Aktan, S. G., Chevrette, L., Coca-Prados, M. and Sarfarazi, M.: Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet., 62: 573-584 (1998).
34. Whitlock, J. P., Jr.: Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol., 39: 103-125 (1999).
35. Kawajiri, K., Watanabe, J., Eguchi, H., Nakachi, K., Kiyohara, C. and Hayashi, S.: Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics, 5: 151-158 (1995).
36. Fujii-Kuriyama, Y., Ema, M., Mimura, J., Matsushita, N. and Sogawa, K.: Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Pharmacogenetics, 5: S149-S153 (1995).
37. Micka, J., Milatovich, A., Menon, A., Grabowski, G. A., Puga, A. and Nebert, D. W.: Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics, 7: 95-101 (1997).
38. Daly, A. K., Fairbrother, K. S. and Smart, J.: Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Toxicol. Lett., 102-103: 143-147 (1998).
39. Garte, S. and Sogawa, K.: Chapter 14. Ah receptor gene polymorphisms and human cancer susceptibility. IARCSci. Publ., 148: 149-157 (1999).
40. Mimura, J., Ema, M., Sogawa, K. and Fujii-Kuriyama, Y.: Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes. Dev., 13: 20-25 (1999).
41. Fujita, H., Kosaki, R., Yoshihashi, H., Ogata, T., Tomita, M., Hasegawa, T., Takahashi, T., Matsuo, N. and Kosaki, K.: Characterization of the aryl hydrocarbon receptor repressor gene and association of its Pro185Ala polymorphism with micropenis. Teratology, 65: 10-18 (2002).
42. Fernandez-Salguero, P., Hoffman, S. M., Cholerton, S., Mohrenweiser, H., Raunio, H., Rautio, A., Pelkonen, O., Huang, J. D., Evans, W. E., Idle, J. R. and Gonzalez, F. J.: A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet., 57: 651-660 (1995).
43. Oscarson, M.: Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab. Dispos., 29: 91-95 (2001).
44. Yamano, S., Tatsuno, J. and Gonzalez, F. J.: The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 29: 1322-1329 (1990).
45. Oscarson, M., Gullsten, H., Rautio, A., Bernal, M. L., Sinues, B., Dahl, M. L., Stengard, J. H., Pelkonen, O., Raunio, H. and Ingelman-Sundberg, M.: Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. PEBS Lett., 438: 201-205 (1998).
46. Oscarson, M., McLellan, R. A., Gullsten, H., Yue, Q. Y., Lang, M. A., Bernal, M. L., Sinues, B., Hirvonen, A., Raunio, H., Pelkonen, O. and Ingelman-Sundberg, M.: Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. PEBS Lett., 448: 105-110 (1999).
47. Nunoya, K. I., Yokoi, T., Kimura, K., Kainuma, T., Satoh, K., Kinoshita, M. and Kamataki, T.: A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther., 289: 437-442 (1999).
48. Oscarson, M., McLellan, R. A., Gullsten, H., Agundez, J. A., Benitez, J., Rautio, A., Raunio, H., Pelkonen, O. and Ingelman-Sundberg, M.: Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. PEBS Lett., 460: 321-327 (1999).
49. Rao, Y., Hoffmann, E., Zia, M., Bodin, L., Zeman, M., Sellers, E. M. and Tyndale, R. F.: Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol., S8: 747-755 (2000).
50. Ariyoshi, N., Takahashi, Y., Miyamoto, M., Umetsu, Y., Daigo, S., Tateishi, T., Kobayashi, S., Mizorogi, Y., Loriot, M. A., Stucker, I., Beaune, P., Kinoshita, M. and Kamataki, T.: Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics, 10: 687-693 (2000).
51. Pitarque, M., von Richter, O., Oke, B., Berkkan, H., Oscarson, M. and Ingelman-Sundberg, M.: Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun., 284: 455-460 (2001).
52. Kitagawa, K., Kunugita, N., Kitagawa, M. and Kawamoto, T.: CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J. Biol. Chem., 276: 17830-17835 (2001).
53. Xu, C., Rao, Y. S., Xu, B., Hoffmann, E., Jones, J., Sellers, E. M. and Tyndale, R. F.: An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun., 290: 318-324 (2002).
54. Hadidi, H., Zahlsen, K., Idle, J. R. and Cholerton, S.: A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Pood Chem. Toxicol., 35: 903-907 (1997).
55. Ariyoshi, N., Sawamura, Y. and Kamataki, T.: A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem. Biophys. Res. Commun., 281: 810-814 (2001).
56. Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T. and Kuroiwa, Y.: Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther., 277: 1010-1015 (1996).
57. Baker, M. T., Olson, M. J., Wang, Y., Ronnenberg, W. C., Jr., Johnson, J. T. and Brady, A. N.: Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of haloethene metabolism. Drug Metab. Dispos., 23: 60-64 (1995).
58. Smith, G., Stubbins, M. J., Harries, L. W. and Wolf, C. R.: Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica, 28: 1129-1165 (1998).
59. Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics, 11: 399-415 (2001).
60. Yamano, S., Nhamburo, P., Aoyama, T., Meyer, U., Inaba, T., Kalow, W., Gelboin, H., McBride, O. and Gonzalez, F.: cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry, 28: 7340-7348, (1989).
61. Sonnichsen, D. S., Liu, Q., Schuetz, E. G., Schuetz, J. D., Pappo, A. and Relling, M. V.: Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther., 27S: 566-575 (1995).
62. Fischer, V., Johanson, L., Heitz, F., Tullman, R., Graham, E., Baldeck, J. P. and Robinson, W. T.: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos., 27: 410-416 (1999).
63. Bort, R., Mace, K., Boobis, A., Gomez-Lechon, M. J., Pfeifer, A. and Castell, J.: Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem. Pharmacol., S8: 787-796 (1999).
64. Klose, T. S., Blaisdell, J. A. and Goldstein, J. A.: Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J. Biochem. Mol. Toxicol., 13: 289-295 (1999).
65. Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I. and Goldstein, J. A.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 11: 597-607 (2001).
66. Yasumori, T., Kawano, S., Nagata, K., Shimada, M., Yamazoe, Y. and Kato, R.: Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. J. Biochem., 102: 1075-1082 (1987).
67. Romkes, M., Faletto, M., Blaisdell, J., Raucy, J. and Goldstein, J.: Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry, 30: 3247-3255 (1991).
68. Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F. and Korzekwa, K. R.: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4: 39-42 (1994).
69. Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M., Miners, J. O., Birkett, D. J. and Goldstein, J. A.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6: 341-349 (1996).
70. Imai, J., Ieiri, I., Mamiya, K., Miyahara, S., Furuumi, H., Nanba, E., Yamane, M., Fukumaki, Y., Ninomiya, H., Tashiro, N., Otsubo, K. and Higuchi, S.: Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics, 10: 85-89 (2000).
71. Dickmann, L. J., Rettie, A. E., Kneller, M. B., Kim, R. B., Wood, A. J., Stein, C. M., Wilkinson, G. R. and Schwarz, U. I.: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol., 60: 382-387 (2001).
72. Kidd, R. S., Curry, T. B., Gallagher, S., Edeki, T., Blaisdell, J. and Goldstein, J. A.: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics, 11: 803-808 (2001).
73. Kimura, M., Ieiri, I., Mamiya, K., Urae, A. and Higuchi, S.: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit., 20: 243-247 (1998).
74. Scordo, M. G., Aklillu, E., Yasar, U., Dahl, M. L., Spina, E. and Ingelman-Sundberg, M.: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol., 52: 447-450 (2001).
75. Shintani, M., Ieiri, I., Inoue, K., Mamiya, K., Ninomiya, H., Tashiro, N., Higuchi, S. and Otsubo, K.: Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin. Pharmacol. Ther., 70: 175-182 (2001).
76. Kaukonen, K. M., Olkkola, K. T. and Neuvonen, P. J.: Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. J. Clin. Pharmacol., 53: 445-449 (1998).
77. de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A. and Goldstein, J. A.: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem., 269: 15419-15422 (1994).
78. de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K. and Goldstein, J. A.: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol., 46: 594-598 (1994).
79. Xiao, Z. S., Goldstein, J. A., Xie, H. G., Blaisdell, J., Wang, W., Jiang, C. H., Yan, F. X., He, N., Huang, S. L., Xu, Z. H. and Zhou, H. H.: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther., 281: 604-609 (1997).
80. Ferguson, R. J., De Morais, S. M., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., Wilkinson, G. R., Sarich, T. C., Wright, J. M., Dayer, P. and Goldstein, J. A.: A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther., 284: 356-361 (1998).
81. Ibeanu, G. C., Blaisdell, J., Ferguson, R. J., Ghanayem, B. I., Brosen, K., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P. and Goldstein, J. A.: A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther., 290: 635-640 (1999).
82. Ibeanu, G. C., Goldstein, J. A., Meyer, U., Benhamou, S., Bouchardy, C., Dayer, P., Ghanayem, B. I. and Blaisdell, J.: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther., 286: 1490-1495 (1998).
83. Goldstein, J. A.: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol., 52: 349-355 (2001).
84. Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T. and Kaneko, E.: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med., 129: 1027-1030 (1998).
85. Furuya, H., Meyer, U. A., Gelboin, H. V. and Gonzalez, F. J.: Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA. Mol. Pharmacol., 40: 375-382 (1991).
86. Komai, K., Sumida, K., Kaneko, H. and Nakatsuka, I.: Identification of a new nonfunctional CYP2C18 allele in Japanese: substitution of T204 to A in exon2 generates a premature stop codon. Pharmacogenetics, 6: 117-119 (1996).
87. Iwahashi, K., Okuyama, E., Furukawa, A., Nakamura, K., Miyatake, R., Matsuo, Y. and Ichikawa, Y.: Novel 2-point linked mutations in the 5'-flanking region of human CYP2C18. Clin. Chim. Acta., 252: 197-199 (1996).
88. Mamiya, K., Ieiri, I., Miyahara, S., Imai, J., Furuumi, H., Fukumaki, Y., Ninomiya, H., Tashiro, N., Yamada, H. and Higuchi, S.: Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Pharmacogenetics, 8: 87-90 (1998).
89. Eichelbaum, M., Spannbrucker, N., Steincke, B. and Dengler, H. J.: Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol., 16: 183-187 (1979).
90. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R. and Smith, R. L.: Polymorphic hydroxylation of Debrisoquine in man. Lancet, 2: 584-586 (1977).
91. Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A. and Gonzalez, F. J.: The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet., 4S: 889-904 (1989).
92. Hanioka, N., Kimura, S., Meyer, U. and Gonzalez, F.: The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. Am. J. Hum. Genet., 47: 994-1001 (1990).
93. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T. and Meyer, U. A.: Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem., 26S: 17209-17214 (1990).
94. Tyndale, R., Aoyama, T., Broly, F., Matsunaga, T., Inaba, T., Kalow, W., Gelboin, H. V., Meyer, U. A. and Gonzalez, F. J.: Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics, I: 26-32 (1991).
95. Gaedigk, A., Blum, M., Gaedigk, R., Eichelbaum, M. and Meyer, U. A.: Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet., 48: 943-950 (1991).
96. Yokota, H., Tamura, S., Furuya, H., Kimura, S., Watanabe, M., Kanazawa, I., Kondo, I. and Gonzalez, F. J.: Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics, 3: 256-263 (1993).
97. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjoqvist, F. and Ingelman-Sundberg, M.: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U.S.A., 90: 11825-11829 (1993).
98. Panserat, S., Mura, C., Gerard, N., Vincent-Viry, M., Galteau, M. M., Jacqz-Aigrain, E. and Krishnamoorthy, R.: DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum. Genet., 94: 401-406 (1994).
99. Evert, B., Griese, E. U. and Eichelbaum, M.: A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedebergs Arch. Pharmacol., 350: 434-439 (1994).
100. Johansson, I., Oscarson, M., Yue, Q. Y., Bertilsson, L., Sjoqvist, F. and Ingelman-Sundberg, M.: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol., 46 : 452-459 (1994).
101. Saxena, R., Shaw, G. L., Relling, M. V., Frame, J. N., Moir, D. T., Evans, W. E., Caporaso, N. and Weiffen-bach, B.: Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum. Mol. Genet., 3: 923-926 (1994).
102. Broly, F., Marez, D., Sabbagh, N., Legrand, M., Millecamps, S., Lo Guidice, J. M., Boone, P. and Meyer, U. A.: An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics, 5: 373-384 (1995).
103. Panserat, S., Mura, C., Gerard, N., Vincent-Viry, M., Galteau, M. M., Jacoz-Aigrain, E., and Krishnamoorthy, R.: An unequal crossover event within the CYP2D gene cluster generates a chimeric CYP2D7 /CYP2D6 gene which is associated with the poor metabolizer phenotype. Br. J. Clin. Pharmacol., 40: 361-367 (1995).
104. Dahl, M. L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M. and Sjoqvist, F.: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther., 274: 516-520 (1995).
105. Marez, D., Sabbagh, N., Legrand, M., Lo-Guidice, J. M., Boone, P. and Broly, F.: A novel CYP2D 6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics, S: 305-311 (1995).
106. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F. and Ingelman-Sundberg, M.: Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther., 278: 441-446 (1996).
107. Daly, A. K., Fairbrother, K. S., Andreassen, O. A., London, S. J., Idle, J. R. and Steen, V. M.: Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics, 6: 319-328 (1996).
108. Masimirembwa, C., Persson, I., Bertilsson, L., Hasler, J. and Ingelman-Sundberg, M.: A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol., 42: 713-719 (1996).
109. Sachse, C., Brockmoller, J., Bauer, S., Reum, T. and Roots, I.: A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics, 6: 269-272 (1996).
110. Yokoi, T., Kosaka, Y., Chida, M., Chiba, K., Nakamura, H., Ishizaki, T., Kinoshita, M., Sato, K., Gonzalez, F. J. and Kamataki, T.: A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics, 6: 39S-401 (1996).
111. Lovlie, R., Daly, A. K., Idle, J. R. and Steen, V. M.: Characterization of the 16 + 9 kb and 30 + 9 kb CYP2D6 XbaI haplotypes. Pharmacogenetics, 7: 149-1S2 (1997).
112. Sachse, C., Brockmoller, J., Bauer, S. and Roots, I.: Cytochrome P4S0 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet., 60: 284-29S (1997).
113. Marez, D., Legrand, M., Sabbagh, N., Guidice, J. M., Spire, C., Lafitte, J. J., Meyer, U. A. and Broly, F.: Polymorphism of the cytochrome P4S0 CYP2D6 gene in a European population: characterization of 48 mutations and S3 alleles, their frequencies and evolution. Pharmacogenetics, 7: 193-202 (1997).
114. Griese, E. U., Zanger, U. M., Brudermanns, U., Gaedigk, A., Mikus, G., Morike, K., Stuven, T. and Eichelbaum, M.: Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics, 8: 15-26 (1998).
115. Leathart, J. B., London, S. J., Steward, A., Adams, J. D., Idle, J. R. and Daly, A. K.: CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics, 8: S29-S41 (1998).
116. Wang, S. L., Lai, M. D. and Huang, J. D.: G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab. Dispos., 27: 38S-388 (1999).
117. Marez-Allorge, D., Ellis, S. W., Lo Guidice, J. M., Tucker, G. T. and Broly, F.: A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype. Pharmacogenetics, 9: 393-396 (1999).
118. Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E. U., Schwab, M. and Zanger, U. M.: Elucidation of the genetic basis of the common ‘intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics, 10: S77-S81 (2000).
119. Shimada, T., Tsumura, F., Yamazaki, H., Guengerich, F. P. and Inoue, K.: Characterization of (+ / -)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics, 11: 143-1S6 (2001).
120. Oscarson, M., Hidestrand, M., Johansson, I. and Ingelman-Sundberg, M.: A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol., 52: 1034-1040 (1997).
121. Kalow, W.: Interethnic variation of drug metabolism. Trends Pharmacol. Sci., 12: 102-107 (1991).
122. Bertilsson, L., Dahl, M. L., Dalen, P. and Al-Shurbaji, A.: Molecular genetics of CYP2D 6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol., 53: 111-122 (2002).
123. Tateishi, T., Chida, M., Ariyoshi, N., Mizorogi, Y., Kamataki, T. and Kobayashi, S.: Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther., 65: S70-S7S (1999).
124. Suzuki, A., Otani, K., Mihara, K., Yasui, N., Kaneko, S., Inoue, Y. and Hayashi, K.: Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics, 7: 41S-418 (1997).
125. Ingelman-Sundberg, M., Oscarson, M. and McLellan, R. A.: Polymorphic human cytochrome P4S0 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci., 20: 342-349 (1999).
126. Guengerich, F. P. and Shimada, T.: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-4S0 enzymes. Chem. Res. Toxicol., 4: 391-407 (1991).
127. Umeno, M., McBride, O., Yang, C., Gelboin, H. and Gonzalez, F.: Human ethanol-inducible P4S0IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry, 27: 9006-9013 (1988).
128. Hayashi, S., Watanabe, J. and Kawajiri, K.: Genetic polymorphisms in the S'-flanking region change transcriptional regulation of the human cytochrome P4S0IIE1 gene. J. Biochem., 110: SS9-S6S (1991).
129. Persson, I., Johansson, I., Bergling, H., Dahl, M. L., Seidegard, J., Rylander, R., Rannug, A., Hogberg, J. and Sundberg, M. I.: Genetic polymorphism of cytochrome P4S02E1 in a Swedish population. Relationship to incidence of lung cancer. PEBS Lett., 319: 207-211 (1993).
130. Hu, Y., Oscarson, M., Johansson, I., Yue, Q. Y., Dahl, M. L., Tabone, M., Arinco, S., Albano, E. and Ingelman-Sundberg, M.: Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol. Pharmacol., 51: 370-376 (1997).
131. Fairbrother, K. S., Grove, J., de Waziers, I., Steimel, D. T., Day, C. P., Crespi, C. L. and Daly, A. K.: Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics, 8: S43-SS2 (1998).
132. Hu, Y., Hakkola, J., Oscarson, M. and Ingelman-Sun-dberg, M.: Structural and functional characterization of the S' -flanking region of the rat and human cytochrome P4S0 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem. Biophys. Res. Commun., 263: 286-293 (1999).
133. Pelkonen, O., Maenpaa, J., Taavitsainen, P., Rautio, A. and Raunio, H.: Inhibition and induction of human cytochrome P4S0 (CYP) enzymes. Xenobiotica, 28: 1203-12S3 (1998).
134. Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C. J., Burk, O., Buntefuss, D., Escher, S., Bishop, C., Koebe, H. G., Brinkmann, U., Klenk, H. P., Kleine, K., Meyer, U. A. and Wojnowski, L.: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, II: 111-121 (2001).
135. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S. and Schuetz, E.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 27: 383-391 (2001).
136. Schuetz, J. D., Beach, D. L. and Guzelian, P. S.: Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics, 4: 11-20 (1994).
137. Kitada, M. and Kamataki, T.: Cytochrome P450 in human fetal liver: significance and fetal-specific expression. Drug Metab. Rev., 26: 305-323 (1994).
138. Finta, C. and Zaphiropoulos, P. G.: The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene, 260: 13-23 (2000).
139. Gonzalez, F., Schmid, B., Umeno, M., Mcbride, O., Hardwick, J., Meyer, U., Gelboin, H. and Idle, J.: Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA, 7: 79-86 (1988).
140. Westlind, A., Lofberg, L., Tindberg, N., Andersson, T. B. and Ingelman-Sundberg, M.: Interindividual differences in hepatic expression of CYP3A: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem. Biophys. Res. Commun., 259: 201-205 (1999).
141. Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V. P., Zheng, W., Raunio, H., Crespi, C. L. and Gonzalez, F. J.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther., 67: 48-56 (2000).
142. Hsieh, K. P., Lin, Y. Y., Cheng, C. L., Lai, M. L., Lin, M. S., Siest, J. P. and Huang, J. D.: Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos., 29: 268-273 (2001).
143. Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweiser, H. W. and Goldstein, J. A.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther., 299: 825-831 (2001).
144. Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U. M., Brockmoller, J., Klenk, H. P., Meyer, U. A., Khan, K. K., He, Y. A., Halpert, J. R. and Wojnowski, L.: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, II: 447458 (2001).
145. Hamzeiy, H., Vahdati-Mashhadian, N., Edwards, H. J. and Goldfarb, P. S.: Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP. Mutat. Res., 500: 103-110 (2002).
146. Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J. and Schuetz, E. G.: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics, 12: 121-132 (2002).
147. Aoyama, T., Yamano, S., Waxman, D., Lapenson, D., Meyer, U., Fischer, V., Tyndale, R., Inaba, T., Kalow, W. and Gelboin, H.: Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem., 264: 10388-10395 (1989).
148. Jounaidi, Y., Hyrailles, V., Gervot, L. and Maurel, P.: Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem. Biophys. Res. Commun., 221: 466-470 (1996).
149. Chou, F. C., Tzeng, S. J. and Huang, J. D.: Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispos., 29: 1205-1209 (2001).
150. Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y. Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., Koch, I., Zibat, A., Brockmoller, J., Halpert, J. R., Zanger, U. M. and Wojnowski, L.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 11: 773-779 (2001).
151. Goodwin, B., Redinbo, M. R. and Kliewer, S. A.: Regulation of Cyp3a gene transcription by the pregnane X receptor. Annu. Rev. Pharmacol. Toxicol., 42: 1-23 (2002).
152. Zhang, J., Kuehl, P., Green, E. D., Touchman, J. W., Watkins, P. B., Daly, A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Wrighton, S. A., Hancock, M., Kim, R. B., Strom, S., Thummel, K., Russell, C. G., Hudson, J. R., Jr., Schuetz, E. G. and Boguski, M. S.: The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics, 11: 555-572 (2001).
153. Hustert, E., Zibat, A., Presecan-Siedel, E., Eiselt, R., Mueller, R., Fuss, C., Brehm, I., Brinkmann, U., Eichelbaum, M., Wojnowski, L. and Burk, O.: Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos., 29: 1454-1459 (2001).